| Assessment Status | Rapid Review Complete |
| HTA ID | 24001 |
| Drug | Liraglutide |
| Brand | Saxenda® |
| Indication | Liraglutide is indicated as an adjunct to a healthy nutrition and increased physical activity for weight management in adolescent patients from the age of 12 years and above with: • obesity (body mass index (BMI) corresponding to ≥30 kg/m2 for adults by international cut-off points) and • body weight above 60 kg* |
| Assessment Process | |
| Rapid review commissioned | 05/01/2024 |
| Rapid review completed | 09/02/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that liraglutide not be considered for reimbursement at the submitted price*. |
*The Applicant is requesting reimbursement in a subgroup of the licensed population, namely:
Adolescent patients between the ages 12 to 16 years with a BMI greater than the 99.5th percentile and two or more of the following co-morbidities:
- Uncontrolled metabolic complications.
- Biomechanical complications requiring treatment or limited mobility.
- Shortness of breath.
- Significant psychosocial complications or concerns.
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations February 2026.